Zentalis Pharmaceuticals
Presence
Zentalis Pharmaceuticals is one of the...
Zentalis Pharmaceuticals is a company listed under the stock ticker ZNTL (US).
Acquisition, funding and merger involving Zentalis Pharmaceuticals.
- Zentalis Pharmaceuticals has just announced a $200 Million fundraising (posted on May 19 2022).
Executives
View the org chart displaying its 17 main executives
Most searched biographies at Zentalis Pharmaceuticals
- Kimberly Blackwell, Chief Executive Officer and Director
- Karan Takhar, Director
- Enoch Kariuki, Director
Popular executive movements at Zentalis Pharmaceuticals
- Cam Gallagher, who was President and Director, is promoted to Interim Chief Financial Officer, President and Director (posted on April 14 2024).
- Melissa Epperly, Chief Financial Officer, has left the company (posted on April 14 2024).
- Kyle Rasbach has joined the company as Chief Business Officer (posted on January 26 2024).
Click here to view some more movements at Zentalis Pharmaceuticals
Create your alert
to follow the executive moves at Zentalis Pharmaceuticals.
Pharmaceuticals
Zentalis Pharmaceuticals has 1,867 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Zentalis Pharmaceuticals
- Press Releases | Zentalis Pharmaceuticals
- Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference | Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Zentalis Pharmaceuticals
- View more press releases Close
Social media about Zentalis Pharmaceuticals
- Zentalis Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Zentalis Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Kimberly Blackwell 
Call Zentalis Pharmaceuticals at +1 212...
